glp-1 drugs canada Health assessing popular diabetes, weight-loss like Ozempic for suicide risk CPHA: Canada Now Second-Largest GLP-1

OK, fine, I admit that I do feel this paper hides the bodies slightly too effectively, in a way that could mislead people who arent experts or that dont read the paper carefully

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

Liraglutide has been reported to lower the BMI by approximately 5% (55) and semaglutide with an average of 15% compared to a placebo (56)

doi: 10.1007/s00125-015-3660-2 17 HabibAMRichardsPCairnsLSRogersGJBannonCAParkerHEet al

Hoare SR

The reproducibility of subjective appetite scores